Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12528285 | 0.84 | CYP17A1 (0.53) | CYP17A1DRD2GLS | |
| SCHEMBL7390375 | 0.82 | CYP17A1 (0.57) | CYP17A1DRD2GLS | |
| SCHEMBL3127225 | 0.79 | CYP17A1 (0.57) | CYP17A1DRD2GLS | |
| SCHEMBL7042995 | 0.79 | DRD2 (0.59) | CYP17A1DRD2GLS | |
| SCHEMBL27167710 | 0.79 | CYP17A1 (0.51) | CYP17A1MMP13DRD2GLS | |
| SCHEMBL1000732 | 0.78 | NR1H4 (0.58) | CYP17A1DRD2GLS | |
| SCHEMBL10999 | 0.78 | SLC6A2 (0.58) | SLC6A2MMP12MMP13 | |
| SCHEMBL16246084 | 0.78 | CYP17A1 (0.58) | CYP17A1DRD2GLS | |
| SCHEMBL5656 | 0.78 | SLC6A2 (0.58) | SLC6A2MMP12MMP13 | |
| SCHEMBL10867 | 0.78 | SLC6A2 (0.58) | SLC6A2MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | CYP17A1 3070/4885SLC6A2 4624/4885MMP12 482/4885 |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LCT, AGXT, PRXL2A | CYP17A1 4014/4885SLC6A2 4292/4885MMP12 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.